Scheld W M
Division of Infectious Diseases, University of Virginia Health Sciences Center, University of Virginia School of Medicine, Charlottesville 22908.
Eur J Clin Microbiol Infect Dis. 1991 Apr;10(4):275-90. doi: 10.1007/BF01967001.
Many discriminative experimental animal models of infection have been utilized in the evaluation of newer fluoroquinolones. In vivo efficacy of many of the newer agents has been shown in experimental models of meningitis, endocarditis, pneumonia, urinary tract infections, pyelonephritis, osteomyelitis, abscesses of various types, septic arthritis, gastroenteritis, salmonellosis, listeriosis, tuberculosis, syphilis, sinusitis, prostatitis and burn wound sepsis, among others. This review focuses on recent developments in a few selected areas. Although the limitations of animal model studies are well described, these results provide a rationale for the appropriate clinical usage of the newer fluoroquinolones in humans.
许多有鉴别力的感染实验动物模型已被用于评估新型氟喹诺酮类药物。许多新型药物的体内疗效已在脑膜炎、心内膜炎、肺炎、尿路感染、肾盂肾炎、骨髓炎、各种类型的脓肿、败血症性关节炎、肠胃炎、沙门氏菌病、李斯特菌病、结核病、梅毒、鼻窦炎、前列腺炎和烧伤创面败血症等实验模型中得到证实。本综述聚焦于几个特定领域的最新进展。尽管动物模型研究的局限性已有充分描述，但这些结果为新型氟喹诺酮类药物在人类中的合理临床应用提供了理论依据。
